Daily oral GLP-1 medication linked to similar weight loss across three menopausal stages
A new analysis presented at the European Association for the Study of Diabetes shows that the oral weight-loss medication orforglipron is equally effective across all menopausal stages. The study suggests the drug provides consistent body weight reduction regardless of a woman's hormonal status.
Why it matters
This finding is significant for obesity treatment, as it indicates that hormonal changes during menopause do not necessarily hinder the efficacy of GLP-1 receptor agonists.
by European Association for the Study of Diabetes
edited by Sadie Harley , reviewed by Andrew Zinin
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Credit: Unsplash/CC0 Public Domain New analyses to be presented at the annual meeting of the European Association for the Study of Diabetes ( EASD ) in Milan, Italy, Sept. 28–Oct. 2, show that orforglipron, a daily oral medication for weight loss and type 2 diabetes, was associated with similar weight loss among women of different ages and at different life stages: before, during and after menopause.
The study is by Dr. Hunter Thomas Hoffman of Eli Lilly and Company in Indianapolis, the manufacturer of orforglipron, and colleagues.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in